Literature DB >> 17272224

Molecular biology of bladder cancer.

Nuno M Luis1, Elena López-Knowles, Francisco X Real.   

Abstract

Bladder cancer is a major cause of health expenses and it presents formidable clinical challenges. Two types of tumors have been identified, papillary and non-papillary. The former are mainly characterized by FGFR3 and chromosome 9 alterations and a low frequency of Tp53 alterations. The latter are characterized by a high frequency of alterations in genes in the p53 and Rb pathways. Chromosome 9 alterations, specially in 9q, are crucial to bladder cancer development and occur in both types of tumors. Progression of some superficial tumors (mainly TaG3 and T1G3) to high-grade, invasive, carcinomas provides evidence of some overlap between the two pathways. Distinct gene expression profiles have been identified in superficial and invasive tumors. The stage is now ready for the clinical application of this knowledge.

Entities:  

Mesh:

Year:  2007        PMID: 17272224     DOI: 10.1007/s12094-007-0003-x

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  15 in total

1.  Cell-cycle control in urothelial carcinoma: large-scale tissue array analysis of tumor tissue from Maine and Vermont.

Authors:  Petra Lenz; Ruth Pfeiffer; Dalsu Baris; Alan R Schned; Mikiko Takikita; M Cristina Poscablo; Molly Schwenn; Alison Johnson; Michael Jones; Masatoshi Kida; Kenneth P Cantor; Nathaniel Rothman; Debra T Silverman; Stephen M Hewitt; Lee E Moore
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-07-03       Impact factor: 4.254

2.  Selenium and risk of bladder cancer: a population-based case-control study.

Authors:  Kristin Wallace; Karl T Kelsey; Alan Schned; J Steven Morris; Angeline S Andrew; Margaret R Karagas
Journal:  Cancer Prev Res (Phila)       Date:  2009-01

3.  Plasma 25-hydroxyvitamin D(3) and bladder cancer risk according to tumor stage and FGFR3 status: a mechanism-based epidemiological study.

Authors:  André F S Amaral; Marinela Méndez-Pertuz; Alberto Muñoz; Debra T Silverman; Yves Allory; Manolis Kogevinas; Josep Lloreta; Nathaniel Rothman; Alfredo Carrato; Manuel Rivas del Fresno; Francisco X Real; Núria Malats
Journal:  J Natl Cancer Inst       Date:  2012-10-29       Impact factor: 13.506

4.  β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation.

Authors:  I Ahmad; J P Morton; L B Singh; S M Radulescu; R A Ridgway; S Patel; J Woodgett; D J Winton; M M Taketo; X-R Wu; H Y Leung; O J Sansom
Journal:  Oncogene       Date:  2010-09-06       Impact factor: 9.867

5.  ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors.

Authors:  Cristina Balbás-Martínez; María Rodríguez-Pinilla; Ariel Casanova; Orlando Domínguez; David G Pisano; Gonzalo Gómez; Josep Lloreta; José A Lorente; Núria Malats; Francisco X Real
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

6.  Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis.

Authors:  I Ahmad; R Patel; Y Liu; L B Singh; M M Taketo; X-R Wu; H Y Leung; O J Sansom
Journal:  Cell Death Dis       Date:  2011-03-03       Impact factor: 8.469

7.  K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder.

Authors:  Imran Ahmad; Lukram Babloo Singh; Mona Foth; Carol-Ann Morris; Makoto Mark Taketo; Xue-Ru Wu; Hing Y Leung; Owen J Sansom; Tomoko Iwata
Journal:  Dis Model Mech       Date:  2011-04-18       Impact factor: 5.758

8.  Deregulation of Rab and Rab effector genes in bladder cancer.

Authors:  Joel R Ho; Elodie Chapeaublanc; Lisa Kirkwood; Remy Nicolle; Simone Benhamou; Thierry Lebret; Yves Allory; Jennifer Southgate; François Radvanyi; Bruno Goud
Journal:  PLoS One       Date:  2012-06-19       Impact factor: 3.240

9.  The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.

Authors:  Julie Earl; Daniel Rico; Enrique Carrillo-de-Santa-Pau; Benjamín Rodríguez-Santiago; Marinela Méndez-Pertuz; Herbert Auer; Gonzalo Gómez; Herbert Barton Grossman; David G Pisano; Wolfgang A Schulz; Luis A Pérez-Jurado; Alfredo Carrato; Dan Theodorescu; Stephen Chanock; Alfonso Valencia; Francisco X Real
Journal:  BMC Genomics       Date:  2015-05-22       Impact factor: 3.969

10.  Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer.

Authors:  C Blick; A Ramachandran; S Wigfield; R McCormick; A Jubb; F M Buffa; H Turley; M A Knowles; D Cranston; J Catto; A L Harris
Journal:  Br J Cancer       Date:  2013-06-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.